Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Royalty Pharma Stories

2014-01-06 08:26:28

NEW YORK, Jan. 6, 2014 /PRNewswire/ -- Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash. (Logo: http://photos.prnewswire.com/prnh/20130812/NY62264LOGO) The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA® (dimethyl fumarate), an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The...

2013-07-19 08:26:46

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research...

2013-07-18 08:28:53

Retains royalty rights to odanacatib and other Celera drug assets MADISON, N.J. and NEW YORK, July 18, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products,...

2013-06-18 08:30:03

NEW YORK, June 18, 2013 /PRNewswire/ -- Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to lapse its offer for Elan Corporation, plc (NYSE: ELN) if, among other things, Elan shareholders approved the Share Repurchase Program. Following Elan's announcement of a sale process, Elan shareholders approved the Share Repurchase Program with 187,484,566 votes FOR and 186,574,867 AGAINST, a margin of 909,699...

2013-06-17 04:22:51

Expresses Disappointment at Elan's Unwillingness to Negotiate Improved Terms in a Recommended Transaction Structured as a Scheme of Arrangement NEW YORK, June 17, 2013 /PRNewswire/ -- Royalty Pharma announced today that Rory Riggs, Chairman and Co-Founder of the Royalty Pharma group, is sending the following open letter to the Board of Directors of Elan Corporation, plc (NYSE:ELN): To the Board of Directors of Elan Corporation: As you know, Elan's shareholders appear poised to...

2013-06-14 16:24:21

Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma's Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward NEW YORK, June 14, 2013 /PRNewswire/ -- Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma believes it to be a clear frustrating tactic that offers shareholders no certainty that a deal will ever be reached. Royalty Pharma calls on...

2013-06-14 04:20:41

VOTE OF ORDINARY SHAREHOLDERS MAY DETERMINE WHETHER ROYALTY PHARMA'S OFFER OF $13 IN CASH PLUS AN UP TO $2.50 CVR WILL BE PERMITTED TO PROCEED NEW YORK, June 14, 2013 /PRNewswire/ -- Royalty Pharma today announces that as of 3:00 pm EDT on Thursday, June 13, 2013 holders of approximately 311 million Elan ADSs, representing more than 81% of the Elan ADSs held in street name, had voted on the Elan Corporation, plc (NYSE: ELN) proposals through Broadridge. Based on a review of those...

2013-06-11 12:29:04

IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPSE ITS OFFER(I),(II) NEW YORK, June 11, 2013 /PRNewswire/ -- Royalty Pharma today announced that it believes Elan's (NYSE: ELN) disclosure in its May 27( )EGM Circular is misleading and inadequate, in Royalty Pharma's view, because it fails to: Regarding the entire package of proposed transactions: disclose that the Theravance, AOP, Speranza and inconsequential...

2013-06-10 20:21:44

Elan's US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to Consider Royalty Pharma's Increased Tender Offer NEW YORK, June 10, 2013 /PRNewswire/ -- Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York federal court. That suit claimed that Royal Pharma's tender offer...

2013-06-07 08:24:15

CVR Allows Shareholders to Participate in Tysabri Royalty Upside for all Indications and Cash Flows, Pre- and Post-Patent Expiration NEW YORK, June 7, 2013 /PRNewswire/ -- Royalty Pharma today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to further increase its offer for Elan Corporation, plc (NYSE: ELN) to $13.00 per share in cash plus a contingent value right ("CVR") worth up to $2.50 per share. The CVR, based on feedback...